Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920293 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT03920293 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 175 participants.
The verdict
NCT03920293, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
Interventions
- DRUG Placebo
- BIOLOGICAL Ravulizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2023-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03920293
The ClinicalTrials.gov registry entry for NCT03920293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03920293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03920293 about?
NCT03920293 is a clinical study titled "Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis". The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT03920293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2019-03-12. Estimated completion is 2023-05-25.
What interventions are being tested in trial NCT03920293?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03920293?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.